Introduction
The mortality risk from cardiovascular disease is much higher in end-stage renal disease (ESRD) than in the general population [1] . In hemodialysis patients, the prevalence of congestive heart failure is 30-40%, and up to 40% have ischemic heart disease [2] .
Natriuretic peptides are released from the cardiac ventricles in response to wall stretch. A precursor peptide, pro-brain natriuretic peptide (proBNP), cleaves into the biologically active BNP and the inactive N-terminal proBNP (NT-proBNP). BNPs cause vasodilatation, natriuresis and inhibition of the renin-angiotensin system [3] . Plasma levels of natriuretic peptides (BNP and NT-pro-BNP) are increasingly used in the emergency setting to exclude or confirm the presence of congestive heart failure in nonrenal patients with acute dyspnea. In the PRIDE study, a reference level for excluding heart failure of NTproBNP <300 pg/ml for both sexes and all ages had a negative predictive value of 99% [4] . The clinical use of NTproBNP in optimizing the treatment of patients with chronic heart failure has been shown by Januzzi et al. [5] . NT-proBNP levels are influenced by factors such as sex, age, fluid status, nutritional status, body mass index, thyroid status and renal function [6] [7] [8] . NT-proBNP increases with the worsening of renal function and is more strongly related to the glomerular filtration rate than BNP [9] . Almost 100% of all patients with ESRD have markedly elevated NT-proBNP [10, 11] . This is caused by both increased secretion as well as decreased renal clearance [12] . NT-proBNP has a longer half-life than BNP and is more stable in vitro [13] .
Previous studies have shown that a single measurement of NT-proBNP is a predictor of mortality in hemodialysis patients [10, 11, 14, 15] and that NT-proBNP levels are higher in dialysis patients with protein energy wasting (PEW) and/or inflammation [8] . Furthermore, using longitudinal data we have previously reported a strong relationship between inflammation and comorbidity, in particular congestive heart failure, whereas variation of NTproBNP is reported to be low in nonrenal patients with stable heart failure [16, 17] . There is limited information on the variation of natriuretic peptides in dialysis patients.
In the present study, serial measurements of NT-pro-BNP and inflammatory markers were analyzed during 3 months. Their relation to clinical characteristics, comorbidity, nutritional status and survival was evaluated. The aim was to study (1) variation of NT-proBNP; (2) which factors influence this variation, and (3) the effect of variation on the prognostic value of NT-proBNP in hemodialysis patients.
Patients and Methods

Patients
A total of 254 prevalent hemodialysis patients from six dialysis units in the Stockholm-Uppsala region were invited to participate in the study. Patients were recruited during the period October 2003 to September 2004. The study protocol was approved by the Ethics Committee of the Karolinska Institutet, Stockholm, Sweden, and has been described previously [16] . Informed consent was obtained from each patient. After initial exclusions, 228 hemodialysis patients were eligible [16] . Thirteen patients lacked sufficient data on NT-proBNP and 4 patients died during the 3-month variation study period. Remaining were 211 patients eligible for NTproBNP analyses.
Patient characteristics at baseline are presented in table 1 . Thirty-six patients had returned to hemodialysis after renal graft loss. All patients were treated with hemodialysis using bicarbonate dialysate and synthetic or semisynthetic membranes (polyamide 128 patients, polysulfone 70 patients, cellosyn 12 patients, polyacrilonitrile 1 patient). Forty-seven patients were treated with high-flux membranes and the remainder with low-flux membranes. In all, 191 patients had dialysis 3 times a week, 15 patients had it 2 times a week and 5 patients more than 3 times a week.
Comorbidity was determined by one clinician (S.S.) at study start using the Davies comorbidity index [16, 18] , which includes ischemic heart disease, left ventricular dysfunction, peripheral vascular disease, diabetes mellitus, malignancy, systemic collagen vascular disease and other significant diseases. The diagnosis of left ventricular dysfunction was based on clinical symptoms, chest X-ray and/or echocardiography. Nutritional status was evaluated at study start using subjective global assessment (SGA), which includes a history of weight loss, incidence of anorexia, incidence of vomiting, muscle wasting, presence of edema and loss of subcutaneous fat [19] . Wasting (PEW) was defined as an SGA score >1.
Survival was determined after a follow-up period of up to 52 months. A total of 99 patients died during follow-up. Patients receiving a kidney transplant were excluded from the analysis at the time of transplantation.
Biochemical Methods
Samples of venous blood were collected at the start of the study and once every month before the dialysis session. Plasma was separated and samples were kept frozen at -70 ° C if not analyzed immediately. NT-proBNP, high-sensitivity C-reactive protein (hs-CRP) and albumin were measured at baseline and weeks 4, 8 and 12 according to certified methods in the Karolinska lab. NT-pro-BNP was analyzed in heparinized plasma by an immunometric assay on an Immulite 1000 Analyzer (Siemens Medical Solutions Diagnostics, Los Angeles, Calif., USA) according to the instructions of the manufacturers. The recommended reference values 140 from the manufacturer for this analysis are 125 pg/ml for people <75 years of age and 450 pg/ml for those >75 years [20] . The upper limit of the analysis is 35,000 pg/ml.
Calculations and Statistical Analyses
To analyze which factors affect NT-proBNP variability, a mixed model was used. The model includes fixed effects (age, sex, dialysis vintage, comorbidity, SGA, study week) and random effects (repeated observations of NT-proBNP and hs-CRP). A second variability analysis, intraclass correlation (ICC), was used to estimate to what extent the NT-proBNP variation is within the same individual versus between individuals [21] .
For survival analysis, study patients were divided into tertile groups based on NT-proBNP values at study start, as follows: low tertile, 279-4,389 pg/ml; middle tertile, 4,390-18,442 pg/ml, and high tertile, 18,443 to >35,000 pg/ml. Six patient groups were defined according to variation of the monthly NT-proBNP levels: (1) NT-proBNP stable within the low tertile; (2) NT-proBNP stable within the middle tertile; (3) NT-proBNP stable within the high tertile; (4) NT-proBNP varying between the low and middle tertiles; (5) NT-proBNP varying between the middle and high tertiles, and (6) NT-proBNP varying between all tertiles. Survival analyses were conducted with Kaplan-Meier survival curves and Cox proportional hazard models. Relative risks for mortality were adjusted for age, sex, comorbidity, hs-CRP, dialysis vintage and nutritional status and presented as hazard ratios with 95% confidence intervals (CIs).
Results
Patient Characteristics and NT-proBNP Levels
NT-proBNP was 30-fold higher in the hemodialysis patients as compared to reference values used to exclude congestive heart failure in acute-onset or worsening symptoms in the general population [22] . Only 1 patient had an NTproBNP level within the reference interval (279 pg/ml). There was a clear variation within individual patients ( fig. 1 ) ; median range of the four NT-proBNP measurements in each patient was 4,102 pg/ml. A total of 25 patients (12%) had NT-proBNP of >35,000 pg/ml (upper limit of the analysis method) throughout the study, and only 3 patients (1.4%) had values constantly below 1,000 pg/ml. The patient characteristics are presented according to groups of variation of NT-proBNP, based on tertiles at study start ( table 2 ) . The groups with NT-proBNP levels within the high tertile during the study were older and had increased comorbidity, worse nutritional status, higher hs-CRP and lower albumin levels.
NT-proBNP Variability
Factors that associated with the variability of NTproBNP were evaluated using a mixed model ( table 3 ) . Inflammation (hs-CRP) had the strongest association with variability in the study population. Worse nutritional status, older age and increased comorbidity were also significantly related to increased variability. Sex and dialysis vintage were not related to NT-proBNP variability. The ICC, calculated from estimates of between-subject and within-subject variation derived from mixed models, showed that 86% of NT-proBNP variation was explained by variation between patients and 14% was caused by variation within patients (ICC 0.86, 95% CI 0.83-0.89). In comparison, 42% of hs-CRP variation in the same cohort was caused by between-patient variation.
Information on ultrafiltration (UF) was available for the baseline dialysis session in 173 patients. As a sensitivity analysis to test the robustness of our results, we added UF volume as an estimate of overhydration into the mixed model. We found no relation between UF volume and variation of NT-proBNP levels. In another step, we excluded the 12% of patients with NT-proBNP levels above the upper limit of the analysis (35,000 pg/ ml). In this analysis, the association between the SGA and NT-proBNP levels was somewhat weaker (p = 0.05), Patients with congestive heart failure and those with PEW (SGA >1) had significantly higher NT-proBNP levels compared to patients without these conditions. No differences in NT-proBNP were observed in patients with or without ischemic heart disease or diabetes mellitus ( table 4 ) .
NT-proBNP Variability and Survival
Survival analyzed by Kaplan-Meier curves was significantly worse across increasing NT-proBNP tertiles at baseline. Figure 2 a shows survival based on NT-proBNP tertiles at study start. As expected, survival was worst in the category of patients that had NT-proBNP within the high tertile. When analyzing monthly variation, survival was worst among patients with persistently high levels during all study periods, followed by patients who varied between medium and high levels of NT-proBNP ( fig. 2 b) . Table 5 shows Cox multiple regressions where the reference group includes patients with low-tertile NT-pro-BNP during the whole study period. The unadjusted (crude) hazard ratio for mortality is only significant for groups with constantly high or medium-high NT-pro-BNP levels. When adjusting for the confounding effects of age, sex, dialysis vintage and comorbidity, the hazard ratio for death is significant for patients with constantly high NT-proBNP, but when adding a surrogate for PEW (SGA) to the model, NT-proBNP was not significantly associated with a higher risk of death.
Discussion
Our study is, to the best of our knowledge, the largest observational study with repeated measurements of NTproBNP in dialysis patients. It provides information on factors that are associated with variation of NT-proBNP in this population. Moreover, it highlights that inflammation and nutritional status are important interacting factors when analyzing the relationship between NT-pro-BNP and survival.
NT-proBNP levels are high and vary over time in hemodialysis patients. To estimate how variation of NTproBNP over time is related to clinical factors and survival, we grouped patients according to their change from low, medium and high levels in a similar fashion as has been done for hemoglobin variability in dialysis patients [23] . Based on NT-proBNP tertiles, 41% of the participants went from one NT-proBNP tertile to another, and 48% entered the high tertile of distribution at some point during the 3-month study.
NT-proBNP variation is strongly associated with variation in CRP levels. Patients with worse SGA, more comorbidity and higher age also have higher variation in NTproBNP levels. The relation between inflammation and PEW is well established in ESRD [24] , and in a previous study of the same patient cohort, we observed that inflammation was strongly linked to congestive heart failure [16] . Booth et al. [25] showed that NT-proBNP levels are more strongly related to markers of volume overload than to cardiac dysfunction and suggest that the marker is elevated in wasted patients. In the present study, we observed that patients with wasting and patients with congestive heart failure had significantly higher NT-proBNP levels than patients without these conditions ( table 4 ). We found that patients that vary into the high tertile of NT-proBNP are older and have higher hs-CRP and a higher degree of comorbidity. This also accords with the findings of Jacobs et al. [26] , who demonstrated that hs-CRP, NT-proBNP and cardiac troponins are significantly related.
We found that the unadjusted hazard ratio for death was increased for patients who had NT-proBNP levels within the high tertile or within the medium to high tertile of distribution. Following adjustment for sex, age and comorbidity, only patients within the high tertile had increased risk of death. When nutritional status was added to the model, the significance was lost. Previous studies have concluded that NT-proBNP is a strong predictor for survival in dialysis patients. In a cohort study on 585 hemodialysis patients with 2 measurements of NT-proBNP 3 months apart, Gutiérrez et al. [27] found that NT-proBNP is a strong prognostic factor for survival. Although albumin was adjusted for, they did not fully adjust for inflammation or nutritional status. Other studies have shown NT-pro-BNP to be a significant predictive factor of mortality in dialysis patients [10, 11, 15, 28] , including one from our own group [8] , but again nutritional status was not accounted for. The role of albumin as a reliable marker of malnutrition in dialysis patients has in the past years been cause for debate. It is perhaps rather to be seen as a marker of illness [29, 30] . In a study on hemodialysis patients without inflammation, serum albumin did not discriminate wellnourished from malnourished patients [31] . On the other hand, albumin is strongly related to inflammation in these patients and a powerful marker for mortality [32] [33] [34] .
Dialysis patients who develop PEW may be at particular risk of not being treated appropriately when it comes to fluid withdrawal [35] . Awareness of the patient's ac- [25, [36] [37] [38] [39] .
Other factors may explain the strong association between wasting and NT-proBNP. NT-proBNP has been shown to be lower in obese patients [40] . It has been hypothesized that adipocytes have a role in the clearance of natriuretic peptides [41] . In the Dallas Heart Study, Das et al. [42] found that lean body mass was more strongly (and inversely) associated with NT-proBNP and BNP levels than fat mass. In dialysis patients, complex associations between inflammation, fluid overload, congestive heart failure and wasting likely explain why the association between NT-proBNP and survival is not as clear-cut as in nonrenal patients.
Based on the present findings, we suggest that NTproBNP should not be used as an independent predictor of mortality in dialysis patients. It should be interpreted in the context of the markedly elevated levels in most patients, the described high inter-and intraindividual variation and the interaction of factors such as nutritional status, inflammation and comorbidity. In this context, it will be of interest to study if longitudinal monitoring of NT-proBNP, nutritional status and inflammation may help to detect early cardiac dysfunction and contribute to a better outcome in dialysis patients.
The strengths of the present study are the inclusion of prevalent nonselected dialysis patients from several units in the Stockholm-Uppsala area and the fact that nutritional status was registered in all participants. Limitations are the lack of complete data on UF and residual renal function. Few trials of NT-proBNP in hemodialysis patients have registered residual renal function. The ADE-MEX trial (approximately 960 peritoneal dialysis patients) did register residual renal function and showed that about 50% of patients were anephric (i.e. glomerular filtration rate <1 ml/min) and that NT-proBNP remained significantly related to outcome even after correction for residual renal function [43] . We also lacked echocardiography for many patients, and the diagnosis of congestive heart failure was primarily based on clinical information from patient charts. This could possibly, but not undoubtedly, underestimate the prevalence of congestive heart failure in this cohort. Existing data vary in their estimations and definitions of congestive heart failure in dialysis patients. The prevalence of congestive heart failure has been reported to be between 15 and 36% [44] [45] [46] .
In conclusion, monthly variation of NT-proBNP levels is not only associated with concurrent changes in inflammation but also nutritional status, age and comorbidity. Due to strong interactions with other recognized predictors, such as nutritional status, NT-proBNP is not an independent marker for mortality in dialysis patients and can only be used as part of a clinical assessment. Further studies are needed before monitoring of NT-proBNP levels can be established in routine clinical assessment of dialysis patients.
